Skip to main content
XtalPi Holdings Limited logo

XtalPi Holdings Limited — Investor Relations & Filings

Ticker · 2228 ISIN · KYG7S12M1051 LEI · 8368004IS42UJ5SVEV76 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 117 across all filing types
Latest filing 2024-09-13 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2228

About XtalPi Holdings Limited

http://www.xtalpi.com

XtalPi Holdings Limited is an innovative research and development platform specializing in accelerating molecular R&D processes. The company provides drug and material science R&D solutions and services to global conglomerates, primarily targeting the biopharmaceutical, material science, and energy/chemical sectors. XtalPi's unique selling proposition is its proprietary technology stack, which integrates quantum physics-based modeling, artificial intelligence (AI) algorithms, and robotics-driven standardized automation. The company operates through business segments that offer modular Drug Discovery Solutions, collaborative R&D services, and an in-house R&D and out-licensing model focused on early-stage drug discovery.

Recent filings

Filing Released Lang Actions
Notification Letter and Request Form to Non-registered Holder - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 95% confidence The document is a letter dated 13 September 2024 from QuantumPharm Inc. addressed to non-registered holders regarding the arrangement for electronic dissemination of corporate communications. It explains how shareholders can access corporate communications electronically or request printed copies. It references various types of corporate communications such as annual reports, interim reports, notices of meetings, proxy forms, and other documents but does not contain any actual financial data, financial statements, or detailed report content. The document is informational and procedural in nature, facilitating shareholder communication preferences rather than presenting any financial or management report. It is also relatively short and serves as a notification about how to receive future reports rather than being a report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and communication about compliance with listing rules, rather than an actual report or announcement of voting results, management changes, or financial results.
2024-09-13 English
Notification Letter to Shareholders - Arrangements on Dissemination of Corporate Communications
Regulatory Filings Classification · 95% confidence The document is a letter from QuantumPharm Inc. dated 13 September 2024, addressing shareholders about the arrangements for dissemination of corporate communications. It references compliance with the Listing Rules of the Hong Kong Stock Exchange and explains how shareholders will receive corporate communications electronically or in printed form upon request. The document does not contain any financial data, results, or detailed reports but rather explains the process and policies for distributing various corporate documents such as annual reports, interim reports, notices of meetings, proxy forms, etc. It is essentially an announcement about how the company will communicate with shareholders going forward, not the report itself or any financial disclosure. The document length is 6333 characters, which is relatively short and consistent with an announcement letter. Therefore, this fits best under Regulatory Filings (RNS), as it is a general regulatory announcement about corporate communication arrangements and does not fit into any other specific category.
2024-09-13 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares of QuantumPharm Inc. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosure of share changes. The content details the cancellation of shares and the updated issued share count. It is a regulatory disclosure about share capital changes, specifically share cancellation, and does not contain financial statements or earnings data. It is not a full report but a regulatory announcement of share capital changes. This fits the definition of a Transaction in Own Shares (POS) filing, which covers share buybacks, cancellations, or sales of treasury shares.
2024-09-11 English
VOLUNTARY ANNOUNCEMENT - INCLUSION OF SHARES IN THE SHANGHAI-HONG KONG STOCK CONNECT AND THE SHENZHEN-HONG KONG STOCK CONNECT PROGRAMS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by QuantumPharm Inc. regarding the inclusion of its shares in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs. It explains the stock connect mechanisms and the effective date of inclusion. The document is short (2582 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an announcement about a capital market access event rather than a report or detailed financial disclosure. Therefore, it fits best under the category of a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2024-09-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report for an equity issuer listed on the Hong Kong Stock Exchange, specifically under Chapter 19B of the Exchange Listing Rules. It provides comprehensive data on movements in authorised share capital, issued shares, treasury shares, share options, and other share-related arrangements for the month ended 31 August 2024. The document is 8024 characters long, which is substantial and contains detailed share capital and securities movement data. It is not an announcement of a report but the report itself. The content aligns with regulatory filings related to share capital and securities movements rather than financial performance, management changes, or other categories. Given the nature of the document and the specific focus on share capital movements and securities, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory submission to the Hong Kong Exchanges and Clearing Limited detailing securities movements and share capital information, which does not fit into more specific categories like Share Issue/Capital Change (SHA) because it includes detailed monthly movements and confirmations as required by the exchange rules.
2024-09-04 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024' and contains detailed unaudited condensed consolidated financial statements including profit or loss, comprehensive income, balance sheet, and cash flows for the six-month period ending June 30, 2024. It also includes notes on accounting policies and revenue breakdowns. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content matches the characteristics of an Interim / Quarterly Report (IR), which provides comprehensive financial data for a period shorter than a full fiscal year. It is not a mere announcement or certification, nor a full annual report (10-K). Therefore, the correct classification is IR with high confidence. H1 2024
2024-08-28 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.